49.20
+0.735(+1.52%)
Currency In USD
| Previous Close | 48.47 |
| Open | 48.06 |
| Day High | 49.26 |
| Day Low | 47.71 |
| 52-Week High | 81.36 |
| 52-Week Low | 44.49 |
| Volume | 1.3M |
| Average Volume | 1.26M |
| Market Cap | 5.81B |
| PE | -9.14 |
| EPS | -5.38 |
| Moving Average 50 Days | 48.86 |
| Moving Average 200 Days | 54.2 |
| Change | 0.74 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $7,387.39 as of February 05, 2025 at a share price of $49.2. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $3,481.95 as of February 05, 2025 at a share price of $49.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
GlobeNewswire Inc.
Jan 30, 2025 12:30 PM GMT
Total of $100,000 Awarded to Five Patient Advocacy Organizationsto Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
GlobeNewswire Inc.
Jan 21, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is o
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
GlobeNewswire Inc.
Jan 13, 2025 12:30 PM GMT
PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Leading Muscle Biology Specialty Biopharma Company S